What is MK-677 (Ibutamoren)?

MK-677 is a non-peptide, orally active growth hormone secretagogue that binds the ghrelin receptor (GHS-R1a). It increases endogenous growth hormone secretion by up to 97% and IGF-1 by 60-79%, taken as a once-daily oral dose. It is not a peptide, not a SARM, and not FDA-approved.

Does MK-677 build muscle?

MK-677 increases fat-free mass (1.1 kg over 2 years in clinical trials), but multiple studies show this does not translate to improvements in muscle strength or physical function. The lean mass gained is likely intracellular water and non-contractile tissue rather than functional muscle fibre.

How does MK-677 affect sleep?

MK-677 increases Stage IV deep sleep by approximately 50% in young subjects and REM sleep by 50% in older adults, confirmed by polysomnography. This is its strongest functional outcome. Bedtime dosing is recommended to optimise these effects.

What is the right MK-677 dose?

Clinical trials used 25 mg/day as the standard dose. A conservative starting dose of 10 mg/day restores IGF-1 by approximately 52% with lower metabolic side effects. Typical cycles are 8-12 weeks followed by a 4-week washout.

Does MK-677 cause insulin resistance?

Yes. MK-677 consistently increases fasting blood glucose (average 5 mg/dL) and HbA1c across clinical trials. Growth hormone opposes insulin action. It is contraindicated in diabetes, prediabetes, and metabolic syndrome.

Is MK-677 safe for the heart?

A hip fracture trial in elderly patients was terminated early due to a congestive heart failure signal (6.5% treatment vs 1.7% placebo). This occurred in patients over 80 with pre-existing cardiac risk. It is contraindicated in heart failure and uncontrolled hypertension.

MK-677 is not FDA-approved, not eligible for compounding under 503A/503B, and is banned by WADA and the DoD. It is sold as a research chemical on the grey market, where products are frequently mislabelled or contaminated.

MK-677 (Ibutamoren): Peptide Profile

Q: Does MK-677 improve bone density?

Used alone, MK-677 increases bone turnover but does not increase bone mineral density. When combined with alendronate (an antiresorptive), femoral neck BMD increased by 4.2% versus 2.5% with alendronate alone. The combination works; monotherapy does not.

The most persistent myth about MK-677 is its classification. While common GH secretagogues like ipamorelin or GHRP-2 are peptides (short amino acid chains requiring injection), MK-677 is a spiropiperidine, a synthetic small molecule engineered for oral bioavailability.

How It Works

MK-677 binds with high affinity to the GHS-R1a receptor (the ghrelin receptor) in the hypothalamus and anterior pituitary. This triggers intracellular signalling via phospholipase C and protein kinase C, releasing growth hormone from pituitary somatotrophs.

Pharmacokinetics

Oral bioavailability: approximately 60-70%.
Tmax: 1-3 hours after oral dosing.
Elimination half-life: 4-6 hours (plasma clearance).
Pharmacodynamic half-life: ~24 hours. A single oral dose keeps IGF-1 elevated for a full day, enabling once-daily dosing.

The Key Distinction

Unlike exogenous GH injection, MK-677 amplifies the amplitude of endogenous GH pulses while preserving pulsatility and natural feedback loops. It does not suppress the endogenous GH/IGF-1 axis. This is a fundamentally different pharmacological profile from recombinant human growth hormone.

MK-677 reliably increases fat-free mass. The two-year aging trial (Nass et al., 2008) showed a 1.1 kg increase in FFM in the treatment group versus a 0.5 kg loss in placebo. The Murphy (1997) dose-response study documented IGF-1 increases of 52% at 10 mg and 79% at 50 mg.

The Hollow Gain

Despite the FFM increase, researchers found no statistically significant improvements in muscle strength or functional performance (gait speed, stair climbing). The gain in mass did not translate to a gain in power.

This identifies what researchers call the body composition paradox: MK-677 promotes nitrogen retention (a classic anabolism marker) but appears to fail at stimulating the synthesis of contractile protein. The resulting lean mass likely represents intracellular water and non-functional tissue rather than dense muscle fibre.

Fat Mass

Total fat mass and visceral fat did not significantly change with treatment. While GH is lipolytic, the potent appetite stimulation from ghrelin receptor activation offsets fat oxidation. A transient 15% increase in basal metabolic rate was documented within 2 weeks in obese subjects (Svensson, 1998), but this effect attenuated by week eight.

MK-677 demonstrates an almost unmatched ability to move laboratory numbers. But across multiple indications, these biomarker wins failed to translate into clinical benefit.

Alzheimer's Disease: IGF-1 Up, Cognition Unchanged

The Sevigny et al. (2008) trial randomised 563 patients with mild-to-moderate Alzheimer's disease to 25 mg/day or placebo for 12 months. IGF-1 increased by 60.1-72.9% over the year. There was zero difference in cognitive decline (ADAS-Cog, CIBIC-plus) between groups.

Bone: Turnover Up, Density Flat

The Murphy et al. (2001) osteoporosis study revealed a parallel increase in both bone formation markers (osteocalcin) and bone resorption markers (N-telopeptide). Because these processes were coupled, the accelerated turnover did not produce net bone accrual. BMD at the spine and hip was largely unchanged when MK-677 was used alone.

When combined with alendronate (an antiresorptive), femoral neck BMD increased by 4.2% versus 2.5% with alendronate alone. The combination works because alendronate blocks the resorption side while MK-677 drives formation.

The Pattern

Across aging, neurodegeneration, and bone health, MK-677 is a master of target engagement that consistently fails at the clinical endpoint. The compound changes the numbers on a lab report but struggles to change outcomes.

Where MK-677 struggled with physical outcomes, it delivered measurable results in the sleep lab. Growth hormone secretion is physiologically coupled with restorative sleep, and as a ghrelin mimetic, MK-677 reinforces this architecture.

Polysomnography Data (Copinschi et al., 1997)

Young subjects: 50% increase in Stage IV slow-wave sleep (the deepest and most restorative phase) and >20% increase in REM sleep.
Older subjects: 50% increase in REM duration and decreased REM latency.
Both cohorts: Marked decrease in abnormal sleep episodes. Frequency of deviations from normal sleep dropped from 42% (placebo) to 8% (high-dose MK-677).

Clinical Significance

The sleep data is MK-677's strongest functional outcome. Unlike the lean mass or bone turnover results, the sleep improvements were both statistically significant and clinically meaningful. Participants reported improved subjective sleep quality, reduced fatigue, and enhanced daytime alertness.

Bedtime dosing is standard for optimising sleep architecture while minimising the appetite spike during waking hours.

The primary pharmacological cost of sustained GH elevation is disruption of glucose metabolism. Growth hormone and IGF-1 naturally oppose insulin action, and Merck's clinical programme identified these effects as early as two weeks into treatment.

Documented Effects

Fasting glucose: Average increase of 0.3 mmol/L (5 mg/dL) in the Nass (2008) trial.
HbA1c: Consistent increases across trials, reflecting a long-term shift toward a pre-diabetic trajectory.
Insulin sensitivity: Impaired glucose tolerance requiring increased insulin production to manage blood sugar.

The Heart Failure Signal

The most serious safety finding came from the Adunsky et al. (2011) Phase IIb hip fracture trial. The study was terminated early: 6.5% of treatment-arm patients developed congestive heart failure versus 1.7% on placebo.

The signal occurred primarily in patients over 80 with pre-existing cardiac vulnerability. The mechanism is GH-induced fluid retention (edema) placing an intolerable burden on compromised cardiovascular systems. This does not mean MK-677 causes heart failure in healthy adults, but it means the compound demands respect for cardiovascular risk factors.

Other Hormonal Effects

Cortisol: Modest, statistically significant increase (~1.7 mcg/dL) in elderly populations, typically remaining within normal limits.
Prolactin: Transient elevations documented. Clinical significance unclear but relevant for monitoring.

MK-677 was developed by Merck & Co. through multiple Phase II trials but was never submitted for FDA approval. The compound failed to achieve functional clinical endpoints despite consistent biomarker success.

Current Legal Status

Not FDA-approved: For any indication. No approved drug substance status.
Not compoundable: Not eligible for compounding under Section 503A or 503B.
WADA prohibited: Category S2 (peptide hormones, growth factors). Banned by the Department of Defense.
Grey market: Sold as a research chemical. Products are frequently mislabelled, misdosed, or contaminated with SARMs.

Emerging Research

At Mass General Brigham, researchers are investigating ibutamoren as a direct immunomodulator for Nonalcoholic Fatty Liver Disease (NAFLD), focusing on its ability to inhibit Th17 cell differentiation via the ghrelin receptor. This represents a mechanism distinct from the GH/IGF-1 axis. Specific NAFLD-related endpoints have not yet been established in completed trials.

The Central Question

MK-677 is a master at changing numbers on a lab report but has consistently struggled to change lives in the clinic. The thirty-year research record is a case study in the limits of biomarker chasing: a compound can hit every pharmacological target and still fail to deliver what patients actually need.

MK-677 sits in a unique position: a compound with 30 years of human data, consistent pharmacological activity, and zero FDA approvals. Its GH/IGF-1 elevation is real. Its sleep architecture effects are real. Its insulin resistance is real. Its heart failure signal in the elderly is real. The question is not whether MK-677 does what it claims, it is whether what it does is worth the metabolic cost in any given individual.

1.Mechanism: Not a Peptide, Not a SARM

How It Works

Pharmacokinetics

The Key Distinction

Explore This Protocol

Safety Triggers

Research Gaps

Contrarian Views

Protocol Reference

Related Research

Increased Strength

Ipamorelin

Muscle Growth: Hypertrophy

Fat Loss: Lipolysis

Bone Density

Skin Elasticity

Stay Ahead of the Research

2.Body Composition: The Functional Gap